FilingSEC EDGAR8-K
PDS Biotechnology Announces Publication of PDS0101 Phase 2 Clinical Results
· SEC accepted
StagePhase 2
Filing content
The company announced the publication of Phase 2 clinical trial results for PDS0101 in combination with pembrolizumab for HPV16-positive head and neck cancer in JAMA Oncology.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…